113 results
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
8 May 24
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for
4:41pm
, and other development milestones. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include … : the unproven nature of CytomX’s novel PROBODY® therapeutic technology; CytomX’s clinical trial product candidates are in the initial stages of clinical
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
8 May 24
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:04pm
that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel PROBODY® therapeutic technology
8-K
EX-3.1
CTMX
CytomX Therapeutics Inc
22 Mar 24
Departure of Directors or Certain Officers
4:06pm
paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding. (3) The term
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
11 Mar 24
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
4:02pm
. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel
8-K
EX-99.1
taw4pg
7 Nov 23
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:05pm
424B3
ftz6i
25 Aug 23
Prospectus supplement
5:36pm
D
z2ha25duiez19
16 Aug 23
$30.00 mm in options, sold $30.00 mm, 4 investors
5:55pm
8-K
EX-99.1
kfz6v
8 Aug 23
CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
rl6769tw ea0qpt992xn
9 May 23
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:12pm
8-K
gzp4d mxg76
21 Nov 22
Entry into a Material Definitive Agreement
8:05pm
8-K
EX-99.1
p4xmy52c
8 Nov 22
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4:09pm